Molecular Monitoring of Chronic Myeloid Leukemia Treated with Imatinib Mesylate

作者
Yuan Wei
出处
期刊:Gothenburg University - Gothenburg University Publications Electronic Archive
摘要

The BCR-ABL fusion gene product is a constitutively activated tyrosine kinase, which is fundamental in the pathogenesis of chronic myeloid leukemia (CML). Imatinib mesylate (imatinib, Glivec® or Gleevec®), a small molecule inhibitor of the BCR-ABL tyrosine kinase, is now the first-line treatment for all newly diagnosed chronic phase CML patients. Imatinib treatment results in a high frequency of complete cytogenetic response (CCgR). Patients in CCgR can be further stratified by the degree of minimal residual disease, measured by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). The present thesis deals with different aspects on molecular monitoring of imatinib treated CML patients. By serially analyzing peripheral blood and bone marrow BCR-ABL transcript levels using qRT-PCR in CML patients commencing imatinib therapy, we found that the major decline in BCR-ABL transcripts occurred within 6 months after start of imatinib treatment. An apparent plateau in BCR-ABL transcript level seems to have been reached after 12-15 months of imatinib treatment, which indicates a stable number of remaining BCR-ABL positive cells. To search for markers associated with molecular response in CML patients treated with imatinib, we studied the mRNA expression of apoptosis-related genes in peripheral blood nucleated cells from chronic phase CML patients commencing imatinib treatment. We found that a lower BAD expression at diagnosis correlates with a better molecular response at 12 months of imatinib therapy. Studies of BCR-ABL kinase domain mutations in imatinib treated CML patients revealed that point mutations were mainly associated with acquired resistance, but not with cytogenetic or molecular disease persistence in CML patients without signs of increasing leukemia burden. Finally we studied “off-target” effects of imatinib on peripheral blood on T-lymphocytes. We found that therapeutic doses of imatinib alter the expression of apoptosis related genes in CD3+ lymphocytes and change the phenotype of CD4+CD28+ T-helper cells.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
flying发布了新的文献求助60
刚刚
sleep完成签到,获得积分10
刚刚
1秒前
洋洋芋发布了新的文献求助10
2秒前
可一可再完成签到 ,获得积分10
3秒前
方方土完成签到,获得积分20
3秒前
科研通AI65的应助被DW采纳,获得10
3秒前
Hello的应助被steplight采纳,获得10
4秒前
隐形曼青的应助被steplight采纳,获得10
4秒前
OK的应助被steplight采纳,获得50
4秒前
无花果的应助被steplight采纳,获得10
4秒前
所所的应助被steplight采纳,获得10
4秒前
思源的应助被steplight采纳,获得10
4秒前
科目三的应助被steplight采纳,获得10
4秒前
田様的应助被steplight采纳,获得10
4秒前
Nole的应助被steplight采纳,获得10
4秒前
秋风的应助被steplight采纳,获得10
4秒前
4秒前
skyleon完成签到,获得积分10
4秒前
4秒前
云淡风轻发布了新的文献求助10
5秒前
5秒前
闪闪的向珊完成签到 ,获得积分10
5秒前
Owen的应助被细心鲂采纳,获得10
6秒前
Hello的应助被范范范采纳,获得10
6秒前
王大胆完成签到,获得积分10
6秒前
7秒前
Maestro_S的应助被帅气的小鸭子采纳,获得20
7秒前
7秒前
7秒前
Zoey完成签到,获得积分10
7秒前
8秒前
rongliy完成签到,获得积分10
8秒前
chole发布了新的文献求助10
9秒前
yi发布了新的文献求助10
9秒前
9秒前
9秒前
1717发布了新的文献求助10
10秒前
脱羰甲酸发布了新的文献求助10
10秒前
方青松发布了新的文献求助10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188353
求助须知:如何正确求助?哪些是违规求助? 9576169
关于积分的说明 21845860
捐赠科研通 7786410
什么是DOI,文献DOI怎么找? 3435292
关于科研通互助平台的介绍 2559588
邀请新用户注册赠送积分活动 2482235